Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Sangamo acquires TxCell for cell therapy

by Ryan Cross
July 27, 2018 | A version of this story appeared in Volume 96, Issue 31

 

Sangamo Therapeutics, the zinc-finger gene-editing company, plans to expand its cell therapy pipeline by acquiring the French biotech firm TxCell for about $84 million. So far most cell therapies are intended to treat cancer, but TxCell is developing regulatory T-cell (Treg) therapies for autoimmune diseases. Sangamo expects to begin a clinical trial next year using genetically engineered Tregs to prevent tissue rejection in organ-transplant patients.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.